BioSpace News Archive

SenesTech, Inc. (NASDAQ: SNES) will report financial results for its fourth quarter and fiscal year 2022, ended December 31, 2022, after the market close on Thursday, March 16, 2023.

A study by Hospital for Special Surgery and other centers found that total hip replacement performed with a cementless prosthesis for a femoral neck fracture led to a higher rate of a second fracture and subsequent revision surgery.

Eli Lilly and Company (NYSE:LLY) announced today that solanezumab did not slow the progression of cognitive decline due to Alzheimer’s disease (AD) pathology when initiated in individuals with amyloid plaque but no clinical symptoms of the disease, known as the preclinical stage of AD1.

Completed all preclinical studies and manufacturing to support PMN310 IND submission to U.S. Food and Drug Administration Preclinical data that further characterize ongoing programs, including PMN310, to be presented in 2023.

MacroGenics, Inc. announced that it has entered into an agreement to sell its royalty interest on future global net sales of TZIELD to a wholly-owned subsidiary of DRI Healthcare Trust for up to $200 million.

Bionomics Limited announced the release of a comprehensive analysis of the data from its Phase 2 PREVAIL study to evaluate the efficacy and safety of BNC210, a novel α7 nicotinic acetylcholine receptor negative allosteric modulator, for the acute treatment of Social Anxiety Disorder.

Curis, Inc. (NASDAQ: CRIS) announced today that it is rescheduling its fourth quarter business update and quarterly investor conference call previously scheduled for Thursday, March 9, 2023 at 4:30 p.m. ET to Monday, March 13, 2023 at 8:30 a.m. ET.

Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research.

Capricor Therapeutics will release its financial results for the fourth quarter and full year ended December 31, 2022, after the market close on Wednesday, March 15, 2023.

NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell therapies, today announced the formation of its Scientific Advisory Board (SAB) comprised of scientific and clinical experts with deep expertise in neurodegenerative diseases.